Heart Failure POC and LOC Devices Market - By Test Type (Proteomic, Metabolomic, Genomic), Technology (Microfluidics, Array-based Systems), End-use (Hospitals, Specialty Clinics, Assisted Living & Homecare Settings) – Global Forecast (2024 – 2032)

Heart Failure POC and LOC Devices Market Size

Heart failure POC and LOC Devices Market size was valued at around USD 91.7 million in 2023 and is estimated to grow at 16.4% CAGR from 2024 to 2032. Heart failure POC (Point-of-Care) and LOC (Low-oxygen concentration) devices are medical devices designed to assist in the diagnosis, monitoring, and management of heart failure, a chronic condition characterized by the heart's inability to pump blood effectively. These devices are intended for use at the point of care, such as clinics, hospitals, or home settings, to provide rapid and convenient assessment of heart function and oxygenation status.
 

The advancement in diagnostic technologies is a significant driver for the heart failure POC and LOC devices market. For instance, National Institutes of Health, in 2023, paper-based microfluidics offers inherent microfluidic benefits along with the performance of lateral flow strips. Further, chemiluminescence techniques on paper microfluidics can perform multiplexed analysis of antibodies like cardiac troponin I (cTnI), heart-type fatty acid-binding protein (H-FABP), and copeptin for acute myocardial infarction diagnosis.
 

Moreover, increasing use of heart pump devices (market size is estimated to account for USD 9.2 billion by the end of year 2032), rising adoption of prosthetic heart valves, advancement in structural heart devices, rising healthcare expenditure globally, government initiatives and funding, and increasing education & awareness, are the stretching factors advancing the growth of the market.
 

Heart Failure POC and LOC Devices Market Trends

The increasing prevalence of heart failure and cardiovascular diseases is a significant driver for market. These diseases are major global health concerns affecting millions of individuals worldwide.
 

• According to the National Library of Medicine, in 2023, heart failure affects more than 64 million people worldwide. As per the same report, in 2021, heart failure was mentioned on 379,800 death certificates (13.4%).
   
• Further, as per the American Heart Association (AHA) report, in 2023, heart disease affects about 2.5% of the U.S. population. Similarly, according to the Journal of Cardiac Failure, in 2023, the overall prevalence of heart failure among U.S. adults has ranged from 1.9% to 2.6% for the overall population.
   
• Early diagnosis and intervention are critical for managing heart failure and CVD effectively and preventing disease progression. POC devices enable rapid assessment of cardiac function, hemodynamic parameters, and oxygenation status at the point of care allow healthcare providers to diagnose heart failure promptly, initiate appropriate treatment, and optimize patient outcomes.
   
• There is a growing emphasis on value-based care and healthcare delivery models that prioritize preventive strategies, early detection, and proactive management of chronic conditions such as heart failure and CVD. POC and LOC devices support these initiatives by enabling timely interventions, reducing hospital readmissions, and improving patient outcomes, thereby lowering healthcare costs, and enhancing the quality of care.
   

Heart Failure POC and LOC Devices Market Analysis

Based on test type, the market is segmented into proteomic testing, metabolomic testing, and genomic testing. The proteomic testing segment is estimated to account for USD 155.9 million by the end of 2032.
 

• Proteomic testing enables comprehensive molecular profiling of proteins, peptides, and biomolecules present in biological samples such as blood, serum, plasma, or urine. By analyzing the protein composition and expression patterns, proteomic testing can identify disease-specific biomarkers, protein signatures, and molecular pathways associated with heart failure, cardiac remodeling, and myocardial dysfunction.
   
• It plays a crucial role in biomarker discovery and validation for heart failure and CVD. By comparing protein profiles between healthy individuals and patients with heart failure, proteomic assays can identify novel biomarkers indicative of disease onset, progression, severity, and prognosis.
   
• Proteomics testing enables early diagnosis and risk stratification of individuals at risk of developing heart failure or experiencing cardiovascular events. Consequently, detecting subtle changes in protein expression or post-translational modifications, proteomic assays can identify high-risk patients, predict adverse outcomes, and guide preventive interventions to mitigate disease progression and complications.
   
• Moreover, advances in proteomic technologies including mass spectrometry, immunoassays, protein microarrays, and multiplexed detection platforms, have enhanced the sensitivity, specificity, and throughput of proteomic testing for heart failure and CVD, thereby accelerating the segmental growth.
   

Based on technology, the heart failure POC and LOC devices market is divided into microfluidics, array-based systems, and other technologies. The microfluidics segment accounted for USD 43.7 million in 2023.
 

• Microfluidic-based devices are characterized by their small size, portability, and integration of multiple functions onto a single chip or platform. These compact devices enable point-of-care testing (POCT) and low-oxygen concentration (LOC) therapy to be performed at the patient's bedside, in ambulatory settings, or even at home, providing rapid results and immediate interventions for heart failure management.
   
• These devices utilize microscale channels, valves, pumps, and reaction chambers to manipulate small volumes of fluids, samples, and reagents with precise control and accuracy.
   
• Further, by reducing sample volume requirements, microfluidic-based assays minimize sample handling, processing time, and assay costs, making them well-suited for POC testing and rapid diagnostics in heart failure and cardiovascular diseases (CVD).
   
• Microfluidic-based systems offer automation and integration of sample preparation, assay execution, and data analysis steps within a single device or platform. These integrated systems streamline workflow, minimize user intervention, and reduce the risk of errors or contamination associated with manual sample handling.
   
• Thus, such aforementioned factors are expected to augment the segmental growth.
   

Based on end-use, the heart failure POC and LOC devices market is divided into hospitals, specialty clinics, assisted living healthcare facilities, homecare settings, and other end-users. The hospitals segment accounted for a market share of 35.9% in 2023.
 

• Hospitals serve as centralized care settings where patients with heart failure and cardiovascular diseases (CVD) receive comprehensive medical care, including diagnosis, treatment, monitoring, and management of their condition. Consequently, they are primary locations for deploying POC and LOC devices for cardiac assessment, hemodynamic monitoring, and oxygen therapy.
   
• Hospitals are equipped with emergency departments, intensive care units (ICUs), cardiac catheterization labs, and specialized cardiac care units where POC and LOC devices are used for rapid assessment, triage, and initiation of therapeutic interventions to stabilize patients and prevent adverse outcomes.
   
• Further, many hospitals have specialized cardiac units or heart failure clinics dedicated to the management of patients with heart failure and CVD. These units provide multidisciplinary care by cardiologists, cardiac nurses, pharmacists, and other healthcare professionals who utilize POC and LOC devices for rapid diagnostics and risk stratification.
   
• These settings perform a wide range of diagnostic tests and monitoring procedures for heart failure patients. For instance, POC devices for cardiac biomarkers (e.g., troponin, BNP) and LOC devices for oxygen therapy are integral to the diagnostic workup and monitoring of heart failure patients in hospital settings, thus escalating the segmental growth.
   

The U.S. heart failure POC and LOC devices market is anticipated to grow at CAGR of 16% during the analysis time.
 

• The U.S. has a significant burden of heart failure and CVD, with millions of individuals affected by these conditions. For instance, according to the Heart Failure Society of America (HFSA), in 2023, about 6.2 million adults in the U.S. have heart failure.
   
• Further, factors such as aging population, sedentary lifestyles, unhealthy diets, and comorbidities contribute to the high prevalence of heart failure in the U.S.
   

Germany heart failure POC and LOC devices market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The country is known for its advanced healthcare system, which includes a network of hospitals, clinics, and healthcare facilities equipped with state-of-the-art medical technologies and devices.
   
• These facilities provide comprehensive medical care, including diagnosis, treatment, and management of heart failure and cardiovascular diseases (CVD), driving the demand for POC and LOC devices in the country.
   

Japan heart failure POC and LOC devices market is expected to grow significantly over the years.
 

• Japan has a growing focus on personalized medicine and remote monitoring solutions for chronic diseases such as heart failure. POC and LOC devices equipped with telehealth capabilities enable remote monitoring of heart failure patients, virtual consultations with healthcare providers, and real-time data transmission for timely interventions and care coordination, enhancing patient engagement and adherence to treatment plans.
   
• The country has been an early adopter of point-of-care testing (POCT) technologies for various medical applications, including cardiac biomarker testing, hemodynamic monitoring, and oxygen therapy.
   

UAE heart failure POC and LOC devices market is anticipated to witness lucrative growth between 2024 – 2032.
 

• UAE has been investing significantly in building and expanding its healthcare infrastructure to meet the needs of its growing population. The country boasts modern hospitals, clinics, and healthcare facilities equipped with state-of-the-art medical technologies and devices, including POC and LOC devices for heart failure management.
   
• It has emerged as a leading destination for medical tourism in the Middle East region, attracting patients from neighboring countries and around the world seeking specialized medical care and advanced treatment options. The availability of cutting-edge medical technologies, including POC and LOC devices, in UAE healthcare facilities contributes to the country's market share in heart failure management.
   

Heart Failure POC and LOC Devices Market Share

The heart failure POC and LOC devices industry is highly competitive, marked by several players striving for market dominance. Providers offer comprehensive devices with improved efficiency and affordability. This includes advancements in reading, automation, data reporting, sensor design, and customization. Competition is driven by factors such as the quality, reliability, performance, cost, and compliance with regulatory standards. Strategic partnerships with companies and healthcare networks play a crucial role in market positioning.
 

Heart Failure POC and LOC Devices Market Companies

Some of the eminent market participants operating in the heart failure POC and LOC devices industry include:

• Abaxis, Inc.
• Abbott Laboratories
• Becton, Dickinson and Company
• bioMérieux S.A.
• BioTelemetry, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Instrumentation Laboratory
• Jant Pharmacal Corporation
• Masimo Corporation
• Novartis AG
• Quidel Corporation
• Siemens Healthineers AG
• Stryker Corporation
• Trinity Biotech
   

Heart Failure POC and LOC Devices Industry News:

• In April 2023, Abbott announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company. This acquisition strengthened the cardiovascular segment including POC and LOC devices. Thus, it expanded the product portfolio and increased the sales of the company.
   
• In February 2023, Danaher Corporation through its subsidiary, Molecular Devices, LLC announced the collaboration with HeartBeat.bio to automate and scale cardiac organoids for high-throughput screening in drug discovery. This collaboration accelerated the POC and LOC devices segment of the company. Thus, expanded the revenue.
   

The heart failure POC and LOC devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Proteomic testing
• Metabolomic testing
• Genomic testing

Market, By Technology

• Microfluidics
• Array-based systems
• Other technologies

Market, By End-use

• Hospitals
• Specialty clinics
• Assisted living healthcare facilities
• Homecare settings
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa